Searching for 3mg tirzepatide? Here's what the dose ladder actually looks like

The decision you're probably trying to make

Most people searching for 3mg tirzepatide are trying to understand one of two things: whether a lower or intermediate dose exists before committing to treatment, or whether a product they've seen advertised is the real thing. Both are genuinely useful questions. The first gets to the heart of how tirzepatide is designed to be taken; the second touches on something the MHRA has been clear about, fake and mislabelled weight-loss medicines circulate online, and unfamiliar dose numbers can be a red flag.

So let's work through what actually exists. The tirzepatide dose schedule in the UK follows a staged escalation. Treatment opens at 2.5mg for the first four weeks. That starter dose isn't a treatment dose in the therapeutic sense; its job is to let your body adjust to the medicine gradually, reducing the likelihood of nausea and other gastrointestinal side effects. After four weeks, the prescriber typically moves the dose to 5mg, and escalation continues in four-week steps as tolerated. The ceiling is 15mg.

There is no 3mg step anywhere in that ladder. If a seller is offering tirzepatide at 3mg, the product is either mislabelled or counterfeit. Worth knowing.

Where the 3mg figure probably came from

The most plausible source of the confusion is Rybelsus, an oral semaglutide tablet licensed in the UK for type 2 diabetes, not weight management. Rybelsus comes in 3mg, 7mg and 14mg tablets, and because semaglutide is also the active ingredient in Wegovy (the weight-loss injection), the two sometimes get conflated. Someone searching for GLP-1 medicines and landing on a product listing for oral semaglutide 3mg may understandably wonder whether tirzepatide has an equivalent.

It doesn't. You can read more about how tirzepatide compares to semaglutide-based treatments if that distinction is relevant to your thinking. The short version: tirzepatide activates two receptors (GIP and GLP-1), while semaglutide activates one, they are different medicines with different dose schedules entirely.

The NHS medicines page for tirzepatide sets out the licensed strengths clearly, and it's worth a read if you want a plain-language overview from an official UK source.

What the real dose schedule means for your decision

Understanding the actual dose steps matters for two practical reasons. First, titration pace. Your prescriber won't necessarily push to the highest dose, many people find a good result at 5mg or 7.5mg, and a prescriber who reviews your progress will recommend the dose that balances effectiveness with tolerability for you personally. The dose a clinical trial reports as its headline figure (SURMOUNT-1 showed approximately 20% average weight loss at 15mg over 72 weeks, published in the New England Journal of Medicine) is not the target dose for every patient.

Second, cost context. Each pen in the UK contains four weekly doses at the same strength. If you're exploring what private treatment involves financially, the Mounjaro pricing page explains how costs vary by dose and what a legitimate private prescription includes. Bear in mind that a genuine prescription covers clinical oversight, not just the medicine itself.

If you want to understand exactly what you receive at a specific strength, the tirzepatide 3ml page covers what that pen format contains and is worth reading alongside pricing information. The tirzepatide pen format and storage is also worth understanding before you start: the KwikPen is pre-filled and refrigerated, with each pen lasting a full month of weekly injections.

How a prescriber decides your starting point

A common misconception is that a prescriber assigns a dose based mainly on how much weight you want to lose. That's not quite how it works. The 2.5mg start is the same for virtually everyone, regardless of their BMI or treatment goals, because the escalation schedule is built around tolerability first and clinical response second. Your prescriber will review your health history, current medicines, and any conditions that affect suitability before confirming whether tirzepatide is appropriate at all.

A quick note on eligibility: the licensed threshold is a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as hypertension or high cholesterol. BMI alone doesn't determine approval. You can also find detail on pack sizes and supply on the tirzepatide 30 page, which is useful if you're planning ahead for ongoing treatment. You can explore weight-loss treatment options if you're still deciding which path suits you, or have a look at how our clinical team is structured if you're thinking about starting with a private prescriber. Our prescribers work through the same eligibility criteria the SmPC sets out, a real clinician reviews your consultation the same day, not an automated system.

If you have questions before starting, the FAQs section covers many of the things people ask us most often, and our team is reachable via the contact page if something specific isn't answered there. When you're ready, start your free consultation and a GPhC-registered Independent Prescriber will review your case the same day.